Director Christophe Jean proposes selling 10,000 Rhythm Pharmaceuticals (RYTM) shares.
Rhythm Pharmaceuticals director Christophe Jean has proposed selling 10,000 common shares of the company, valued at an aggregate market value of $1,074,800. The shares were acquired through stock options on November 17, 2026, with Morgan Stanley Smith Barney LLC listed as the broker for the proposed transaction. This proposed sale is detailed in a Form 144 SEC filing.
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Rhythm Pharmaceuticals (RYTM) saw an 8% increase in its stock price following a report that Eli Lilly (LLY) is considering acquiring the company, along with Viking Therapeutics (VKTX), in the obesity market. This report comes after AstraZeneca (AZN) reportedly made a $124 per share offer for Rhythm last month. Eli Lilly's proposal is rumored to be around $150 per share with a contingent value right.
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
Rhythm Pharmaceuticals presented two-year Phase 3 results for setmelanotide at ObesityWeek 2026, demonstrating sustained weight reductions in patients with acquired hypothalamic obesity (HO). The study showed significant mean BMI reductions in both continuous setmelanotide recipients and those who switched from placebo. The drug, which previously received expanded FDA approval for various rare genetic obesity syndromes, maintained a safety profile consistent with prior trials.
Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR (RYTM:NASDAQ)
Rhythm Pharmaceuticals' stock increased by 8% following a report that Eli Lilly is considering acquiring two companies in the obesity market, one of which is Rhythm. This news comes after a separate report of AstraZeneca's bid for a competitor. The specific offer for Rhythm Pharmaceuticals is reported to be $150 per share with a CVR.
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Rhythm Pharmaceuticals presented new data at ObesityWeek® 2026, including two-year results from the Phase 3 TRANSCEND trial which showed that continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity (HO). Additionally, a global expert panel established and presented a consensus definition and diagnostic criteria for acquired HO, aiming to improve recognition and consistent diagnosis of this rare neuroendocrine disease. These findings highlight the potential benefits of setmelanotide and provide a framework for earlier and more accurate diagnosis of acquired HO.
The Technical Signals Behind (RYTM) That Institutions Follow
This article from Stock Traders Daily analyzes Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), highlighting key technical signals and institutional trading strategies. It presents three distinct AI-generated trading plans—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis suggests a prevailing positive sentiment in the near and mid-term, with a potential mid-channel oscillation pattern in play.
Did Quarterly Revenue Growth Just Shift Rhythm Pharmaceuticals (RYTM) Investment Narrative?
Rhythm Pharmaceuticals (RYTM) recently reported third-quarter 2026 results, showing revenue of US$92.13 million and a net loss of US$41.37 million, indicating growing commercial scale for its rare disease business. The company remains in an investment-heavy phase, with ongoing R&D and commercialization spending for IMCIVREE, an MC4R focused pipeline. Analysts have varying perspectives, with some seeing significant upside potential from IMCIVREE's label expansion opportunities, while others focus on competition risk.
Rhythm Pharmaceuticals at Stifel 2026 Healthcare Conference: launch gains pace
Rhythm Pharmaceuticals presented at the Stifel 2026 Healthcare Conference, detailing strong early prescription growth for IMCIVREE in acquired hypothalamic obesity (AHO) following its March 2024 FDA approval, with over 700 start forms and 500 unique prescribers. The company is also advancing bivamelagon as its lead next-generation asset, plans expansion into Japan and Europe in 2027, and anticipates a sharp rise in spending for clinical work and international launches in 2027, despite being currently self-sustaining.
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued On Third Quarter Earnings
Rhythm Pharmaceuticals (RYTM) recently reported strong third-quarter 2026 results, with revenue of US$92.13 million, leading to a significant increase in its share price. The company is viewed by some as 15% undervalued, with a fair value of $134, based on the potential of its rare disease drug IMCIVREE and future portfolio expansion in genetic obesity. However, another perspective suggests the stock looks expensive on sales, trading at a P/S ratio of 28.1x compared to an industry average of 9.7x, indicating a premium on current revenue.
AstraZeneca Proposes $10 Billion Rhythm Pharmaceuticals Acquisition
AstraZeneca has reportedly proposed an acquisition of Rhythm Pharmaceuticals for $10 billion. This potential deal would significantly expand AstraZeneca's portfolio.
Race for Rare Obesity Drug Dominance: AstraZeneca Offers ₩13.6 Trillion to Acquire Rhythm Pharma
AstraZeneca has offered to acquire Rhythm Pharmaceuticals for approximately $10 billion (₩13.6 trillion) to enter the rare obesity treatment market, driven by the promising Phase 2 results of Rhythm's drug candidate, vibamelagone, licensed from LG Chem. This move highlights a broader shift in the pharmaceutical industry towards rare obesity treatments, but safety concerns, including patient deaths and cardiac abnormalities in clinical trials, remain a significant challenge for commercialization. Other companies like Neurocrine Biosciences and Aardvark Therapeutics have also faced safety hurdles with their rare obesity drug candidates.
Rhythm Pharmaceuticals (RYTM) Stock Looks Stretched Following Its New Financing Deal
Rhythm Pharmaceuticals' stock has seen a significant rise, but its current US$112.28 price and a high Price-to-Sales (P/S) ratio of 27.7x suggest it might be overvalued, especially after securing a new US$750m term loan and an amended license for bivamelagon. These financing deals mean a larger portion of future sales will go to licensors and lenders before shareholders, raising concerns about the company's valuation relative to its sales and future profitability. Analysts and community narratives, however, offer differing views on the stock's potential.
JP Morgan maintains Rhythm Pharmaceuticals at Overweight, lowers price target to $142 from $145
JP Morgan has reiterated its "Overweight" rating for Rhythm Pharmaceuticals but slightly decreased its price target from $145 to $142, representing a 2.1% reduction. This new price target suggests a 26.5% upside from the stock's closing price on November 6th of $112.28. Other recent analyst actions for Rhythm Pharmaceuticals within the last 30 days show price targets ranging from $114 to $166.
Rhythm Pharmaceuticals gains on report of additional bidder
Rhythm Pharmaceuticals (RYTM) saw its stock rise by 4.2% following reports of a second bidder, speculated to be one of the world's largest pharmaceutical companies, making a counteroffer. This development comes after a WSJ report indicated AstraZeneca (AZN) had previously made an almost $10 billion offer for Rhythm. Rhythm Pharmaceuticals, with a market cap of $6 billion, is scheduled to present at two upcoming healthcare conferences.
AstraZeneca Makes USD 10 Billion Bid for Obesity Drugmaker Rhythm Pharmaceuticals
AstraZeneca has reportedly made a $10 billion offer to acquire Rhythm Pharmaceuticals, an obesity drugmaker. The British drugmaker's offer was about $124 per share last month, leading to a significant increase in Rhythm's stock price. AstraZeneca had previously shown interest in Rhythm, which specializes in treatments for rare metabolic disorders and severe obesity.
Guggenheim maintains Rhythm Pharmaceuticals at Buy, raises price target to $147 from $143
Guggenheim has reiterated its "Buy" rating for Rhythm Pharmaceuticals and increased its price target from $143 to $147, suggesting a 32.8% upside from the recent closing price. This adjustment follows several other positive analyst actions on the company, with recent price targets ranging from $114 to $166.
AstraZeneca Weighs Roughly $10 Billion Takeover of Rhythm Pharmaceuticals, Sending Shares Up 28%
AstraZeneca is reportedly weighing a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a rare-disease and obesity drugmaker. The proposal, valued at up to $134 per share including milestone payments, has caused Rhythm's shares to jump 28%. This acquisition would be pursued through AstraZeneca's Alexion rare-disease unit and would expand its specialty-medicine pipeline, particularly into the growing obesity market with Rhythm's Imcivree drug.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca recently made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech company specializing in treatments for metabolic conditions and severe obesity. The offer, at $124 a share, would expand AstraZeneca's portfolio of rare disease treatments. Following the news, Rhythm's shares surged 28%, closing at over $110 a share.
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
Rhythm Pharmaceuticals (NASDAQ: RYTM) shares jumped 28% after The Wall Street Journal reported that AstraZeneca (NASDAQ: AZN) offered $10 billion to acquire the biotech company. The U.K.-based drugmaker reportedly offered $124 per share last month, aiming to expand its portfolio of rare disease treatments, particularly in severe obesity. Rhythm's market capitalization closed at approximately $7.7 billion following the surge.
Citizens raises Rhythm Pharmaceuticals price target on Imcivree launch
Citizens has increased its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $166 from $160, maintaining a Market Outperform rating, due to the strong early performance of Imcivree's launch for hypothalamic obesity. The company has seen significant commercial momentum, with over 700 start forms received and robust revenue growth. Additionally, Rhythm Pharmaceuticals recently surpassed Wall Street expectations in its third-quarter earnings.
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals announced that the National Institute for Health and Care Excellence (NICE) has expanded its guidance for IMCIVREE® (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome (BBS). This update, based on additional clinical evidence, allows adults living with BBS in England, Wales, and Northern Ireland to access funded treatment through the NHS. The expanded guidance acknowledges the significant burden of hyperphagia and obesity associated with BBS on patients' quality of life.
Rhythm Pharmaceuticals Expects to Dose First Phase III Patients in January
Rhythm Pharmaceuticals plans to initiate dosing of the first patients in a Phase III trial for bivamelagon for HO in January. The company also announced a $350 million royalty buy-down and reported third-quarter revenue of $92 million, with CEO David Meeker calling the U.S. launch an "excellent start."
Rhythm Pharmaceuticals Q3 Earnings Call Highlights
Rhythm Pharmaceuticals reported strong third-quarter global net product sales of $92.1 million, a 29% sequential increase, driven primarily by the successful U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international presence with a recent Japan launch and ongoing European market access efforts. Rhythm also amended its bivamelagon license agreement with LG Chem, reducing future royalty obligations in exchange for installment payments.
Rhythm Pharmaceuticals Q3 2026 Earnings Call Transcript
Rhythm Pharmaceuticals reported strong Q3 2026 revenue of $92 million, driven by a successful U.S. launch of Imcivree for acquired hypothalamic obesity (HO) and the commencement of its launch in Japan. The company also announced the initiation of its Phase 3 bivameligon HO study, targeting a 52-week trial, and plans to start screening patients by year-end, alongside an amended bivameligon licensing agreement with LG Chem to reduce future royalty obligations. These strategic moves and financial bolstering, including a new $750 million term loan facility, are expected to support bivameligon development and global commercial execution.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 Beats Consensus, but Launch Execution and Spending Weigh on Shares
Rhythm Pharmaceuticals (NASDAQ:RYTM) surpassed Q3 consensus estimates with strong revenue growth from IMCIVREE, especially driven by its U.S. launch in acquired hypothalamic obesity. Despite narrowing losses and expanding the product's global reach, the shares traded lower due to increased operating expenses for multiple commercial launches, complex financing decisions, and the high burden of proof for continued sequential growth. Investors are closely watching the conversion of patient start forms to reimbursed therapy and the trajectory of future expenses.
Rhythm Pharmaceuticals earnings beat by $0.10, revenue topped estimates
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported stronger-than-expected third-quarter results, with EPS beating analyst estimates by $0.10 at $-0.61 and revenue surpassing consensus by $6.66M, reaching $92.1M. Despite the positive earnings, the company's stock has seen a decline of 19.19% in the last three months and 11.00% over the past year.
LG Chem Expands Obesity Drug Licensing Deal with Rhythm Pharmaceuticals to $855 Million
LG Chem has significantly expanded its licensing agreement with Rhythm Pharmaceuticals for bivamelagon, an oral drug candidate for rare forms of obesity, increasing the total deal value to $855 million from an initial $305 million. The amended agreement, now valued at approximately 1.15 trillion won, reflects the drug's promising clinical development and includes additional upfront payments, increased milestone payments, and a revised royalty structure. Bivamelagon, an MC4R agonist, showed positive results in a Phase 2 trial and is expected to advance to global Phase 3 trials this year, offering an oral alternative to existing injectable treatments.
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced strong Q3 2026 financial results, with global net product revenue from IMCIVREE reaching $92.1 million, a 29% increase from the prior quarter, driven by strong U.S. launch momentum and the commercial launch in Japan. The company also reported over 700 patient start forms for IMCIVREE in acquired hypothalamic obesity (HO) and detailed the advancement of bivamelagon into pivotal development for Prader-Willi syndrome. Additionally, Rhythm secured a five-year term loan facility for up to $750 million and amended its licensing agreement with LG Chem for bivamelagon.
Rhythm Pharmaceuticals (RYTM) Revises LG Chem Deal And Adds $750 Million Loan, Is It Still Cheap?
Rhythm Pharmaceuticals (RYTM) is gaining investor attention after revising its global license deal with LG Chem for bivamelagon and securing a new US$750 million term loan. While some narratives suggest the stock is 30% undervalued with a fair value of $134, Simply Wall St's DCF model indicates an even wider margin, pricing it well below an estimated future cash flow value of $474.53, despite ongoing net losses and clinical execution risks. The company, focused on genetic obesity, is seen as a "BUY" by some due to expected double-digit revenue growth and an expanding portfolio.
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals and LG Chem have amended their exclusive license agreement for bivamelagon, an investigational oral MC4R agonist. The revised terms include Rhythm making $350 million in additional fixed payments over four years and a simplified 1% royalty on global net sales of its MC4R portfolio, replacing the previous low-to-mid-single digit structure. To support this, Rhythm also secured a five-year, $750 million term-loan facility led by KKR’s HealthCare Royalty and Blackstone.
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history
Rhythm Pharmaceuticals, Inc. (RYTM) is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. The company's stock closed at $93.44 and its lead product candidate is IMCIVREE (setmelanotide) for various obesity syndromes, with several other drug candidates in clinical trials. RYTM has shown significant returns over 3 and 5 years, outperforming the S&P 500.
Rhythm Pharmaceuticals Inc. (RYTM) Earnings, Actual EPS, EPS Estimates & Results
Rhythm Pharmaceuticals Inc. (RYTM) reported its Q3 '26 earnings, surprising positively on both EPS and revenue. The company reported an EPS of -$0.61, beating the estimated -$0.71, and revenue of $92.13M, surpassing the estimated $85.57M. For the full year 2026, Rhythm Pharmaceuticals anticipates Non-GAAP Operating Expenses between $360M and $380M.
Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143
Citi has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US), maintaining its target price at $143. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals, Inc. (RYTM) is anticipated to surpass earnings estimates for the quarter ended September 2026, driven by higher revenues. The company is expected to report a quarterly loss of $0.68 per share, a 17.1% year-over-year improvement, with revenues projected to increase by 64.7% to $84.47 million. The Zacks Earnings ESP indicates a likely positive surprise, as the Most Accurate Estimate is higher than the Zacks Consensus Estimate, combined with a Zacks Rank of #3.
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Japan Drug Launch
Rhythm Pharmaceuticals has launched IMCIVREE in Japan for acquired hypothalamic obesity, making it available to an estimated 5,000 to 8,000 patients with National Health Insurance reimbursement. This expansion into a new reimbursed rare disease market is a key catalyst for the company, although it remains unprofitable and highly reliant on its lead therapy. Investors will now focus on the efficiency of Rhythm's local infrastructure build-out and its ability to convert regulatory approval and NHI listing into consistent treatment starts.
Rhythm Pharmaceuticals (RYTM) Launched IMCIVREE In Japan, Is It Still A Bargain?
Rhythm Pharmaceuticals has launched IMCIVREE in Japan for acquired hypothalamic obesity, targeting 5,000-8,000 patients, which could significantly expand its rare disease franchise. Despite a recent 15% year-to-date share price dip, analysts and an internal valuation model suggest the stock is undervalued by around 33%, with a fair value target of $134-$140. However, the company remains unprofitable with a high P/S ratio, indicating potential risks if growth forecasts aren't met.
Rhythm Pharmaceuticals, Inc. Estimates – NASDAQ:RYTM
This article provides an overview of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) financial data and analyst estimates on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Rhythm Pharmaceuticals, Inc. Estimates – FWB:1RV
This article provides an overview of Rhythm Pharmaceuticals, Inc. (FWB:1RV) on the Frankfurt Stock Exchange, focusing on its financial data and analyst estimates available through TradingView. It highlights sections for income statements, balance sheets, cash flow, dividends, and earnings, comparing actual results with various estimates. The content serves as a financial data exploration tool, not investment advice.
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that it will host a conference call and webcast on Tuesday, November 3, 2026, at 8:00 a.m. ET, to report its third-quarter 2026 financial results and provide a corporate update. Additionally, company executives will participate in upcoming investor conferences, with live webcasts available on their investor relations website. The company also provided detailed information about its lead asset, IMCIVREE® (setmelanotide), and important safety information.
Two healthcare conferences will feature Rhythm’s CEO and CFO after its Nov. 3 results call.
Rhythm Pharmaceuticals (RYTM) will report its third-quarter 2026 financial results and provide a corporate update on November 3, 2026, with a live conference call and webcast. Following this, CEO David Meeker will participate in the Guggenheim Healthcare Innovation Conference on November 9, and CFO Hunter Smith will join a Stifel Healthcare Conference fireside chat on November 11. The company, focused on rare neuroendocrine diseases, will make webcasts of these events available on its investor relations website.
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast on Tuesday, November 3, 2026, at 8:00 a.m. ET, to report its third quarter 2026 financial results and provide a corporate update. The company also announced its participation in two upcoming investor conferences in November. Additionally, the press release detailed information about Rhythm Pharmaceuticals and its lead asset, IMCIVREE® (setmelanotide), including its indications and important safety information.
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ: RYTM) has significantly outperformed the market over the past five years, generating an average annual return of 51.51%. An initial investment of $1,000 in RYTM stock five years ago would now be worth $7,926.65, highlighting the substantial impact of compounded returns.
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that it will host a conference call and webcast on Tuesday, November 3, 2026, to discuss its third-quarter 2026 financial results and provide a corporate update. Additionally, the company's CEO and CFO are scheduled to participate in separate investor conferences in early November. Live webcasts of these events will be available on the company's investor relations website.
Guggenheim keeps USD 143 target for Rhythm Pharmaceuticals stock
Guggenheim has reiterated a Buy rating and a $143.00 price target for Rhythm Pharmaceuticals (RYTM) following the company's strong second-quarter 2026 revenue of $71.26 million, a 46.90 percent year-over-year increase. Despite continued losses, the growing revenue, primarily from IMCIVREE, underpins the analyst's bullish outlook. The stock's performance and upcoming Q3 earnings report on November 3, 2026, will be crucial for investors, as the valuation depends on further commercial adoption and operating discipline.
Did Japan Launch Just Shift Rhythm Pharmaceuticals (RYTM) Investment Narrative?
Rhythm Pharmaceuticals (RYTM) has commercially launched IMCIVREE in Japan for acquired hypothalamic obesity, a move expected to open access to an estimated 5,000 to 8,000 patients. This launch, backed by strong Phase 3 data, could significantly influence the company's investment narrative by providing a new reimbursed market and testing its ability to scale internationally. While it adds a defined patient pool, the company still faces operating losses and high R&D spending, making IMCIVREE adoption and international execution critical swing factors.
Rhythm Pharmaceuticals (RYTM) Dropped, So What Is Driving Attention Now?
Rhythm Pharmaceuticals (RYTM) recently launched IMCIVREE in Japan for acquired hypothalamic obesity, which has reset investor attention despite a recent decline in its 1-year and 90-day share price returns. The stock is currently trading at a significant discount according to some analyst targets and intrinsic value estimates, with a "most popular narrative" pegging fair value at $134, suggesting it is 36% undervalued. However, its high P/S ratio of 24.7x, compared to an industry average of 11.1x, indicates potential valuation risk.
Rhythm Pharmaceuticals (RYTM) Dropped, So What Is Driving Attention Now?
Rhythm Pharmaceuticals (RYTM) has launched IMCIVREE in Japan for acquired hypothalamic obesity, leading to renewed attention despite a recent decline in its stock performance. The company is considered by some to be 36% undervalued, with a fair value estimated at $134, though its high P/S ratio of 24.7x suggests potential valuation risk. The article advises investors to scrutinize the company's fundamentals and consider both optimistic and cautious viewpoints.
JPMorgan cuts target to USD 145.00 for Rhythm Pharmaceuticals stock
JPMorgan lowered its price target for Rhythm Pharmaceuticals (RYTM) to USD 145.00 from USD 146.00 on October 15, 2026, while maintaining an "Overweight" rating. The stock was trading at USD 86.17 on October 16, 2026, down 2.05% on Nasdaq. Rhythm Pharmaceuticals reported Q2 2026 revenue of USD 71.3 million, up 47%, but remained loss-making with a USD 50.4 million loss.
William Blair Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $206
William Blair has initiated coverage of Rhythm Pharmaceuticals (RYTM.US) with a Buy rating. The firm has set a price target of $206 for the company's stock. This new rating and price target reflect William Blair's positive outlook on Rhythm Pharmaceuticals' future performance.
William Blair initiates Rhythm Pharmaceuticals stock with outperform rating By Investing.com
William Blair has initiated coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with an outperform rating and a $206 price target, significantly above its current trading price of $87.97. The firm projects Imcivree, Rhythm's approved drug for rare neuroendocrine diseases, to achieve $5 billion in peak global sales by 2034, driven by its recent approval for acquired hypothalamic obesity. This optimistic outlook is supported by strong early launch performance and recent regulatory approvals in Japan, positioning Imcivree for substantial market penetration.